Condition 1: End-stage renal disease. Condition 2: Nonorganic sleep disorders. End-stage renal disease Nonorganic sleep disorders
Conditions
Interventions
Intervention 1: Intervention group: Patients in the intervention group are prescribed one 220 mg zinc sulfate tablet daily for the first month and then two zinc sulfate tablets (440 mg) daily for the
Sponsors
Shahroud University of Medical Sciences
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients with breast and blood cancer undergoing chemotherapy with low sleep quality (Global Score <5), Chemotherapy for at least the last four months, Perform chemotherapy for at least once every 15 days, Do not take any sleeping drugs for at least the past month, Having informed consent to participate in research.
Exclusion criteria
Exclusion criteria: Patients with cancers other than breast and blood Use supplements containing zinc or fish oil at least one month before the study Existence of severe heart and respiratory diseases for at least one month Patients who have had a bone marrow transplant and then returned to chemotherapy History of severe mental illness for at least the last three months History of severe mental illness for at least the last three months
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Sleep quality assessment. Timepoint: Once a month. Method of measurement: Ask the patient and using the standard Petersberg Sleep Quality Assessment Questionnaire. | — |
Secondary
| Measure | Time frame |
|---|---|
| CRP measurement. Timepoint: Once a month. Method of measurement: Laboratory method. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactFateme Hasanifard
Shahroud University of Medical Sciences
Outcome results
None listed